Primary hyperparathyroidism;Hyperparathyroidie primitive

Nephrologie

Volumn 21, Issue 6, 2000, Pages 283-290

  Hertig, A ^a   Maruani, G ^a   Paillard, M ^a   Houillier, P ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Calcium sensor; Hypercalcemia; Primary hyperparathyroidism

Indexed keywords

CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CYCLIN D1; DNA; ESTROGEN RECEPTOR; PARATHYROID HORMONE; VITAMIN D RECEPTOR;

BONE DISEASE; CALCIUM BLOOD LEVEL; CARCINOGENESIS; GENE MUTATION; HUMAN; HYPERCALCEMIA; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROLITHIASIS; PARATHYROID ADENOMA; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PRIMARY HYPERPARATHYROIDISM; REVIEW; GENETICS; HYPERPARATHYROIDISM; SECRETION;

HUMANS; HYPERPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PARATHYROID HORMONE;

EID: 0033641710     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers
2. Calcium-regulating hormones and the kidney
3. Cloning and characterization of an extra-cellular Ca2+ -sensing receptor from bovine parathyroid
4. PTH receptor coupling to phospholipase C is an alternate pathway of signal transduction in bone and kidney
5. Hyperparathyroidism common and polymorphic condition as illustrated by seventeen proved cases from one clinic
6. A page out history of primary hyperparathyroidism
7. Primary hyperparathyroidism
8. The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965-1992
9. Thyroid cancer following scalp irradiation
10. Divalent cation metabolism Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism
11. Chromosome mapping of genes on the short arm of chromosome 11: Parathyroid hormone gene is at 11p15 together with the genes for insulin, c-Harvey-ras I, and β-hemoglobin
12. 5' Flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3
13. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3
14. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas
15. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type I
16. Cyclin D1/PRAD1 expression in parathyroid adenoma - An immunohistochemical study
17. Multiple endocrine neoplaisa type 1 gene maps to chromosome 11 and is lost in insulinoma
18. Thakker RVClinical studies of multiple endocrine neoplasia type 1
19. Mutation and cancer: Statistical study of retinoblastoma
20. Association of parathyroid tumors in multiple endocrine neoplasia type I with loss of alleles on chromosome 11
21. Positional cloning of the gene for multiple endocrine neoplasia-type 1
22. Parathyroid mitogenic activity in plasma from patients with familial multiple endocrine neoplasia type I
23. Obvious mRNA and protein expression but absence of mutations of the RET proto-oncogene in parathyroid tumors
24. Vitamin D receptor genotypes in primary hyperparathyroidism
25. Mutations in the human Ca2+ -sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism
26. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma
27. p53 Abnormalities in human parathyroid carcinoma
28. Hereditary hyperparathyroidism-jaw tumor syndrome: The endocrine tumor gene HRPT2 maps to chromosome 1q21-31
29. Primary Hyperparathyroidism: Still Evolving?
30. Dose-response relationships for radiation-induced hyperparathyroidism
31. Psychologic symptoms before and after parathyroid surgery
32. Plasma insulin disturbances in primary hyperparathyroidism
33. Osteoblastic gene expression during adipogenesis in hematopoietic supporting murine bone marrow stroma cells
34. The increased risk of death of primary hyperparathyroidism - An update
35. Premature death in patients operated on for primary hyperparathyroidism
36. Survival and renal function in untreated hypercalcemia. Population-based cohort study with 14 years of follow-up
37. Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up
38. The parathyroid adenomas; a study of 322 cases
39. Nephrolithiasis and bone involvement in primary hyperparathyroidism
40. Cell kinetics in parathyroid adenomas: Evidence for decline in rates of cell birth and tumor growth, ssuming clonal origin
41. Primary hyperparathyroidism
42. The effect of parathyroidectomy on the recurrence of nephrolithiasis
43. Successul parathyroidectomy in primary hyperparathyroidism: A clinical follow-up study of 212 consecutive patients
44. A 10 year prospective study of primary hyperparathyroidism with or without parathyroid surgery
45. Renal stones and primary hyperparathyroidism: Natural history of renal stone disease after successful parathyroidectomy
46. Receptors for PTH and PTH-rP: Their biological importance and functional properties
47. Circulating levels of IL-6 and TNF-α are elevated in primary hyperparathyroidism and correlate with markers of bone resorption
48. Endogenous production of tumor necrosis factor by primary cultures of murine calcarial cells: Influence on IL-6 production and osteoclast development
49. Production of interleukin 6 in human osteoblasts and human bone marrow stromal cells: Evidence that induction by interleukin 1 and tumor necrosis factor-alpha is not regulated by ovarian steroids
50. Therapeutic controversies in primary hyperparathyroidism
51. Bone structure in postmenopausal hyperparthyroid, osteoporotic and normal women
52. Measurement of the subcutaneous fat in the distal forearm by single photon absorptiometry
53. Body weight and bone mineral density in post-menopausal women with primary hyperparathyroidism
54. Fracture incidence in post-menopausal women with primary hyperparathyroidism
55. Risk of age-related fractures in patients with primary hyperparathyroidism
56. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: Clinical course and considerations bearing on the need for surgical intervention
57. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures
58. Primary Hyperparathyroidism and the risk of fracture: A population-based study
59. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism
60. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism
61. Detection of primary hyperparathyroidism, with special reference to its occurrence in hypercalciuric females with 'normal' or borderline serum calcium
62. Normocalcemic primary hyperparathyroidism
63. Normocalcaemic primary hyperparathroidism
64. Masked primary hyperparathyroidism
65. Primary hyperparathyroidism with intermittent hypercalcaemia: Serial observations and simple diagnosis by means of an oral calcium tolerance test
66. A comparative study of serum ultrafiltrable, ionized, and total calcium in the diagnosis of primary hyperparathyroidism in patients with intermittent or no elevation in total calcium
67. Vitamin-D deficiency and primary hyperparathyroidism
68. Evidence for skeletal resistance to parathyroid hormone in magnesium deficiency. Studies in isolated perfused bone
69. Normocalcemic primary hyperparathyroidism: Resistance to PTH effect on tubular reabsorption of calcium
70. Experimental hyperparathyroidism from multiple isologous parathyroid transplants: Homeostatic effect of simultaneous thyroid transplants
71. The relation of serum calcium and immunoparathormone levels to parathyroid size and weight in primary hyperparathyroidism
72. Direct comparison in vivo and in vitro of suppressibility of parathyroid function by calcium in primary hyperparathyroidism
73. Relation between parathyroid cell mass and plasma calcium concentration in normal and uremic subjects
74. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure
75. Determinants of parathormone secretion in primary hyperparathyroidism
76. Mutational analysis of the extracellular Ca2+ -sensing receptor gene in human parathyroid tumors
77. Molecular overtones in primary hyperparathyroidism
78. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism
79. Is the clinical expression of primary hyperparathyroidism a funciton of the long-term vitamin D status of the patient?
80. Suppression of parathyroid hormone by intravenous 1,25(OH)2D3: A role for a lowered set-point
81. Renal mass and reserve of vitamin D: Determinants in primary hyperparathyroidism
82. Vitamin D receptor polymorphisms correlate to parathyroid cell function in primary hyperparathyroidism
83. Estrogen receptor gene polymorphism in postmenopausal primary hyperparathyroidism
84. Consensus development conference panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus development conference statement
85. Vertebral osteopenia: A new indication for surgery in primary hyperparathyroidism
86. 123 the best procedure to locate enlarged glands before surgery?
87. Treatment with oestrogens of primary hyperparathyroidism in post-menopausal woman
88. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women
89. Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density
90. Effects of mild asymptomatic primary hyperparathyroidism on bone mass on women with and without estrogen replacement therapy
91. Medical management of primary hyperparathyroidism
92. A first generation calcimimetic coumpound (NPS R-568) that acts on the parathyroid cell calcium receptor: A novel therapeutic approach for hyperparathyroidism
93. The effect of the calcimimetic drug NPS R-568 on parathyroid hormone secretion in primary hyperparathyroidism
94. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism